Esperamos poder encontrarnos en la Jornada de Uro-Oncología. Rosario 2024 en octubre! UroUNR Diego Barreiro Federico Ferraris Juan Pablo Sade Nicolás Mainardi Sociedad Argentina de Urología🇦🇷

#EAU24 PARPi + ARPI Combos for 1L mCRPC: A SR & MA Rashid K. Sayyid UroToday.com

PARPi/ARPI vs PBO/ARPI
📌3 trials
📌rPFS: HR 0.65, 95%CI 0.56-0.76
📌OS: HR 0.84, 95% CI: 0.72-0.98
📌Gr ≥3 TEAEs: RR 1.45
📌Gr ≥3 anemia: RR 6.22

Una revisión completa 2024 sobre el status actual de PET-PSMA

☑️ Indicaciones
☑️ Comparación con otros métodos
☑️ Guidelines

👇

sciencedirect.com/science/articl…

UroTarget Diego Barreiro Juan Pablo Sade Danny Mena - nuclear medicine DR CARVAJAL FLoscoMD Federico Ferraris Fabián YABER, MD PhD Julian G. Rojas Nuclear Medicine World

66 años, biopsia GLEASON 7 (3+4), PSA 584 ng/mL.

✅ estadificación inicial.
✅ PET-PSMA: compromiso local, no compromiso nodal, lesiones osteolíticas

Cual sería su manejo ?

Encuesta 👇

UroTarget Juan Pablo Sade FLoscoMD Mauricio Fernandez L Diego Barreiro Federico Ferraris Fabián YABER, MD PhD

#ESMO23 Louise Emmett ANZUP presents: ENZA-P (ANSUP 1901) phase 2 trial results of Enza versus Enza + Lu-177 PSMA-617 in mCRPC #prostatecancer 👉Improved PSA PFS and rPFS with combo👇OncoAlert UroToday.com PCF Science Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology

ᵁʳᵒᵁᴺᴿ ✅ Jornada Uro-Oncología. Rosario 2023. 27/10/23. Los esperamos a todos!!! Sociedad Argentina de Urología🇦🇷 Asociación Argentina de Oncología Clínica (AAOC) Urooncologia.arg Fabián YABER, MD PhD Juan Pablo Sade Diego Barreiro Federico Ferraris Gonzalo Taetti Nicolás Mainardi

PET PSMA en la estadificación inicial: Más del 50% de los pacientes con metástasis óseas en centellograma / gammagrama óseo fueron negativos en PET PSMA.

Pacientes condenados a ADT y sus efectos adversos cuando eran localizados.

UroTarget Thomas Hope Michael Hofman

Just in👉 Eur J Cancer EORTC : Analysis of ph3 TITAN trial patient-level data (n=1052)👉⬆️OS, time to CRPC with apalutamide regardless of disease volume/denovo mCSPC #prostatecancer Doublet active in most Axel S. Merseburger Anders Bjartell t.ly/mHi5a OncoAlert UroToday.com

Sociedad Argentina de Urología🇦🇷 Endo Society SIU-Urology Association Française d'Urologie - AFU Urología Uruguaya SMU México Confederación Americana de Urología (CAU) Sociedad Peruana de Urología AEU Norberto Bernardo John Denstedt Olivier Traxer Clovis Fraga Tenório Pereira Mariano Sebastian Gonzalez Moderadores de lujo! Pablo Contreras Dr. Pablo Valladares - Urólogo 🇦🇷 Georgina Gentili Gabriel Barusso Federico Ferraris Diego Barreiro María Belén Romero Echeverría Christian Cristallo Juan Camean

Great talk by Ploussard Guillaume Combination of systematic and targeted #biopsy should still be the gold standard to detect clinically significant #ProstateCancer and allow better prognostic and treatment counseling also due to lower rates of Gleason Score upgrading from biopsy to RP

CORE trial presented at #ESTRO23 about SOC vs SOC & SBRT in oligometastatic lung, breast or prostate cancer
Randomised signal finding study
👉 SBRT well tolerated
👉 HR 0.79 difference > 5mo 👍

In well selected patients - solitary tumors < 7 cm, no or unilateral hydronephrosis, minimal CIS - results with TMT are comparable to Radical Cystectomy

#patientchoice #bladdercancer #BladderCancerMonth23

thelancet.com/journals/lanon…

The Lancet Oncology Bladder Cancer Advocacy Network

Resection Techniques During Robotic Partial Nephrectomy: A Systematic Review #Enucleation #Enucleoresection #partialnephrectomy #roboticsurgery European Urology Open Science
spkl.io/601445Gcn

Maha Hussain summarizing doublet/triplet treatment for #mCSPC based on #TITAN #ENZAMET #ARASENS #PEACE1 . Which patients benefit most from triplet T suppression+NHT+docetaxel? Based on #ENZAMET mainly synch HV. Interesting to see responses to questions asked #AUA2023

Breaking news from #AUA23 Amer. Urol. Assn. : Sia Daneshmand, M.D. presents 1st results from SunRISE-1 trial 👉TAR-200 (local gemcitabine delivery system in bladder) in BCG refractory high-risk non-muscle invasive #bladdercancer 👉 amazing ~73% complete response 👇OncoAlert UroToday.com

First Analysis of Safety/Efficacy of UGN-101 for Ureteral Tumors UroToday.com #AUA23

📌 136 renal units, 47 cases w/ ureteral tumors
📌 No difference (renal pelv vs ureter) in:
- 1st endo eval
- Recur Rate
- Prog Rate
📌 5.4% rate of new ureteral stenosis

EMBARK: 3 arm enza/LHRH, LHRH only, enza only
BCR post-RP or XRT (PSADT≤9 mo), CT/bone scan: neg mets
1⃣ endpoint: MFS in enza/LHRH vs LHRH arm (HR:0.42, p<0.0001)
🔷OS favors combo (HR:0.59, p=0.014)
🔷All key 2⃣ endpoints in favor of combo
🔷No new safety sig
UroToday.com #AUA23

Rx Patterns of Systemic Rx for mCSPC (MP11) UroToday.com #AUA23

**NHT Rx increased
- Chemo, first gen AA, & LHRH monoRx: unchanged or decreased since 2015

**Med Onc: more NHTs than urologists (45% vs 19%)

**Urologists: more LHRH monoRx than Med Onc (69% vs 38%)

Ideal candidates for bladder-sparing treatment of bladder cancer Sophia Kamran, MD #AUA23

Se viene el II curso sobre Uro-Teragnóstico PSMA en LATAM
100% online. Gratuito. Junto a Diego Barreiro Federico Ferraris Sociedad Argentina de Urología🇦🇷 Inscripciones 👇🏼
uroteraglatam.com